VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Stopped early · Phase 2

Conditions studied: Invasive Aspergillosis, Invasive Pulmonary Aspergillosis

In brief

The purpose of the trial is to evaluate the safety and efficacy of a new antifungal with a novel mechanism of action in immunocompromised adults with invasive aspergillosis.

Key facts

Study ID

NCT03327727

Run by

Vical

People needed

4

Starts

2018-02-20

Expected to finish

2019-01-14

Last updated by the study team

2019-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Acute Leukemia (AML or ALL) patient or allo-HCT recipient with a diagnosis of IA

You may not qualify if…

• Pregnant or breastfeeding
• IA involving sites other than lungs and sinuses
• Graft failure, acute or extensive chronic GvHD
• Uncontrolled diabetes

Where it is running

• University of Alabama at Birmingham Hospital, Division of Infectious Diseases — Birmingham, Alabama, United States
• UC San Diego Moores Cancer Center — La Jolla, California, United States
• UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases — Sacramento, California, United States
• Christiana Care Health Services, Department of Medicine — Newark, Delaware, United States
• Medical College of Georgia at Augusta University — Augusta, Georgia, United States
• DMC Harper University Hospital — Detroit, Michigan, United States
• University of Minnesota, Department of Medicine — Minneapolis, Minnesota, United States
• Washington University School of Medicine, Division of Infectious Disease — St Louis, Missouri, United States
• The University of Texas Health Science Center, Department of Internal Medicine — Houston, Texas, United States
• Fred Hutchinson Cancer Research Center (FHCRC) — Seattle, Washington, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States
• University Hospital Antwerp (UZA), Department of Hematology — Edegem, Antwerp, Belgium
• General Hospital Saint-Jan, Department of Hematology — Bruges, Belgium
• Jules Bordet Institute, Department of Infectious Disease — Brussels, Belgium
• University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology — Leuven, Belgium
• UCL Mont-Godinne University Hospitals, Department of Hematology — Yvoir, Belgium
• Hamilton Health Sciences, Infectious Disease Research — Hamilton, Ontario, Canada
• Toronto General Hospital — Toronto, Ontario, Canada
• McGill University Health Centre (MUHC), Division of Infectios Diseases — Montreal, Quebec, Canada
• Grenoble University Hospital Center, Department of Hematology — Grenoble, France
• South Lyon Hospital Center — Pierre-Bénite, France
• Hautepierre Hospital — Strasbourg, France
• University Hospital Jena — Jena, Germany
• Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology — Munich, Germany
• Chonnam National University — Hwasun, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.